Descriptive characteristics of the EMRPC reference population by diabetes type
| Characteristics | Abstracted T1D (n=195) | Abstracted T2D (n=240) | Not abstracted (n=4967) |
| EMR variables | |||
| Age at index, median (IQR) | 42 (31–54) | 67 (56–76) | 66 (57–75) |
| Male | 95 (48.7%) | 131 (54.6%) | 2667 (53.7%) |
| Cumulative Patient Profile terms* | |||
| Definite T1D | 152 (77.9%) | <6 | 37 (0.7%) |
| Possible T1D | 21 (10.6%) | 11 (4.6%) | 17 (0.3%) |
| T2D | 8 (4.0%) | 142 (59.2%) | 3017 (60.7%) |
| Renal insufficiency† | 13 (6.5%) | 26 (10.8%) | 103 (2.1%) |
| Any insulin use | 195 (100.0%) | 240 (100.0%) | 831 (16.7%) |
| Bolus insulin use | 172 (88.2%) | 160 (66.7%) | 359 (7.2%) |
| Metformin use | 14 (7.2%) | 142 (59.2%) | 3814 (76.8%) |
| Non-insulin, non-metformin antihyperglycemic agent use | 0 (0%) | 0 (0.0%) | 2378 (47.9%) |
| BMI (mean±SD) | 27±7 | 32±7 | 32±7 |
| Administrative data variables | |||
| Age at diabetes incidence, median (IQR) | 25 (15–34) | 50 (42–58) | 56 (47–64) |
| Pediatric diabetes | 58 (29.7%) | 0 (0%) | 14 (0.3%) |
| Any insulin use‡ | 48 (92.3%) | 133 (90.5%) | 457 (16.3%) |
| Bolus insulin use‡ | 47 (97.9%) | 116 (78.9%) | 242 (53.0%) |
| Metformin use‡ | <6 | 79 (53.7%) | 1722 (61.6%) |
| Non-insulin, non-metformin glycemic agent use† | <6 | <6 | 1045 (37.4%) |
| Insulin pump | 63 (32.3%) | <6 | 17 (0.3%) |
| Hospital codes | |||
| T1D DKA (ICD-10) | 38 (19.5%) | <6 | 11 (0.2%) |
| T2D DKA (ICD-10) | 8 (4.1%) | 13 (5.4%) | 27 (0.5%) |
| Any DKA (ICD-9+ICD-10) | 58 (29.7%) | 15 (6.3%) | 43 (0.9%) |
| T1D | 46 (23.6%) | 13 (5.4%) | 49 (1.0%) |
| T2D | 42 (21.5%) | 172 (71.7%) | 2266 (45.6%) |
| eGFR (mean±SD) | 101.4±24.9 | 75.1±28.0 | 80.3±21.7 |
*Definite T1D: T1D, T1DM, latent autoimmune diabetes, LADA, juvenile diabetes, juvenile-onset diabetes, juvenile-onset diabetes, diabete de type 1, diabète juvenile, diabète type 1, DB1. Possible T1D: type 1, IDDM, insulin-dependent diabetes, insulin-dependent diabetes, Schmidt, polyglandular. T2D: type 2 diabetes, T2D, T2DM, NIDDM, mature onset, diabete du type 2, non-insulin-dependent diabetes, non-insulin-dependent diabetes, non-insulin-dependent diabetes, non-insulin-dependent diabetes, non-insulin-dependent diabetes, diet-controlled diabetes, diet-controlled diabetes, diabète type 2, DB2.
†Renal insufficiency defined as eGFR ≤30 (or if end-stage renal disease documented for abstracted charts).
‡The denominator for medication use using administrative data was individuals who had any medication claim within ±365 days of index date, since not all individuals have medication data available in the administrative data.
BMI, body mass index; DB1, diabète type 1; DB2, diabète type 2; DKA, diabetic ketoacidosis; eGFR, estimated glomerular filtration rate; EMR, electronic medical record; EMRPC, Electronic Medical Records Primary Care; ICD, International Classification of Diseases; IDDM, Insulin-dependent diabetes mellitus; LADA, Latent Autoimmune Diabetes in Adults; NIDDM, non-insulin dependent diabetes mellitus; T1D, type 1 diabetes; T2D, type 2 diabetes; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabete mellitus.